As a malaria professional you are supposed to keep track of what is happening in our field. That's nothing new. As scholars, researchers, policy makers, doctors, students, etc. we read about new developments, we read scientific articles, and follow the news. And in doing so we are familiar with who is doing what, follows what approach, and is seeking for new solutions to end our common enemy. Again, that is nothing new. But allow us to challenge you...
MIT ALUMNI SUGGEST MALARIA ELIMINATION STRATEGIES FOR AFRICA
7 JUNE 2014
At a Reunion of the Class of 1959 in June 2014 under the Great Dome of MIT in Cambridge, Massachusetts, several suggestions were developed for an Exit Strategy from the fight against malaria in Africa. Malaria currently kills about a million Africans per year, mostly children who succumb to the extreme fevers transmitted by night-biting mosquitoes.
Roll Back Malaria today released a small video about football player Didier Drogba - who suffered malaria and is now an ambassador for our cause.
We ask our readers: What do you think of this video? Will it serve its purpose? Will it reach its target audience?
We are curious to know your thoughts. Is this good money spent on advocacy or a simplified message only mentioning nets?
The social press release is attached to this blog.
If we limit ourselves to the conventional approaches to fighting malaria - drugs, bednets and biocides - the future looks bleak. It looks like an endless war. The war started about 1950 when DDT and chloroquine looked like perfect weapons. But since then the development of resistance has shown us how ephemeral they were. The mosquitoes began to eat DDT for breakfast, and the malaria parasites learned to swim in chloroquine. Historians are showing us that malaria has incredible tenacity in Africa. We long for a solution to this horrible problem - an Exit Strategy.
I appreciate the publication of my first paper on economic benefits from suppressing malaria in Africa, printed in the MWJ of 2014 v5 n4 and cited on the MWJ webpage. I demonstrated that the return on investment in malaria suppression was about 6.5 to 1, a really good investment, don't you think?
Mass Drug Administration (MDA) is a tantalizing tool that can support elimination efforts and help dramatically knock down malaria prevalence. Why isn’t it more widely used?
by George Jagoe
Almost a century after Dr. Israel Kligler initiated a malaria elimination campaign in Mandate Palestine, the undersigned met in Jerusalem to honour his exemplary approach that consisted of an integrated attack on malaria that ultimately led to its disappearance.
In many ways, the disease burden of malaria in Africa today resembles that of Palestine when Kligler first arrived. His success – a toolbox that included larval mosquito control, swamp drainage, quinine prophylaxis and treatment, community education - played a major role in making the Holy Land habitable and productive.
Learning from Success
Over the past 60 years, conferences on malaria have increased from maybe one per decade to multiple conferences annually. The 1950 Kampala Malaria Conference set the parameters for the 1955 Global Malaria Eradication Programme, followed 40 years later, 1992 and 1996, with the meetings in Dakar and Amsterdam that galvanised WHO and international support to eradicate malaria. Roll Back Malaria, the Global Fund, the Gates Foundation and other major international donors took us to the 21st century goal of malaria elimination.
Rubin Hall, Forchheimer Student Center, Ein-Kerem Campus, Jerusalem
8:30-9:00 Coffee/Tea (reception area adjoining Rubin Hall)
9:00-9:30 CONFERENCE OPENING - GREETINGS:
- Prof. Yehuda Neumark. Director, Braun School of Public Health and Community Medicine, Hebrew University of Jerusalem
- Dr. Sanford F. Kuvin. Founder & Chairman of the International Board, Sanford F. Kuvin Center for the Study of Infectious and Tropical Diseases, Hebrew University of Jerusalem
- Prof. David Lichtstein. Dean, Faculty of Medicine, Hebrew University of Jerusalem
- Dr. Rob Dixon. Deputy Head of Mission, British Embassy in Israel
- Dr. Gabriel E. Alexander. Jewish National Fund/Keren Keyemeth LeIsrael
Four years ago, after working for six years as a hospital and pre-hospital emergency doctor in Spain, I accepted a position as a remote site doctor in Sierra Leone. Until then malaria was an obscure, almost phantasmagorical, condition to me.
It is with great sadness that I report the passing of my friend, colleague and my former PhD student Dr. Ernst-Jan Scholte, yesterday, 16 March 2014. Although obituaries are normally written for scientists that died at an old age and had a massive track record in our field, I feel the urge to commemorate and remember this great person in front of you all at MalariaWorld. He became only 40 years of age - after fighting cancer for a year.
Ernst-Jan first contacted me in 1998 when he was still a biology student at the Wageningen University. At that time I was working in Nairobi for the International Centre of Insect Physiology and Ecology (ICIPE). Ernst-Jan (or EJ as many called him) wanted to study mosquitoes and do an internship with me for six months. He was lucky. Within a week after he arrived in Kenya we undertook a wonderful safari to the border with Tanzania, visiting and hiking in a Masai area where I had previously worked on tsetse flies. EJ loved it from day one. He fell in love with Africa, its people and its wildlife, and was extremely motivated in his work. I will never forget the nights we camped out in the bush together...
We know some really good things about suppressing malaria in Africa. Suppressing malaria boosts the productivity of adults, so they can grow more rice, maize or corn. Suppressing malaria saves the lives of children whom we cherish.
The freely available book titled "Artemisia annua,Artemisinin, ACTs & Malaria Control in Africa: Tradition, Science and Public Policy", has been updated by the author, Dana Dalrymple, and has been expanded with an Annex (Annex 7), titled: "The Early Role of Novartis in ACT Development" (pp. 189-192).
The book is attached to this blog. We are grateful to Dr. Dalrymple to make this updated version available for free to MalariaWorld subscribers.
The MW team.
Despite real progress in much of Africa, the two big elephants left in the room are Nigeria and the Congo. Because of poor infrastructure, continuing civil war, and very unstable political conditions, it is hard to imagine how we can attack malaria in the Congo. Although the US PMI has added them to their list, we all know it will be a long time before anything significant can be organized there.
Organizing indoor spray programs or bednet distribution takes a stable MOH, and is difficult in the midst of civil war.
This year World Health Day has its focus on vector-borne diseases, including malaria. The World Health Organization has set specific goals for this day, and is asking the international community working on malaria and other vectors to pay special attention towards protection from vector-borne diseases.
Chers Confreres et Colleagues,
The US Presidential Malaria Initiative (PMI) began in 2005 in Angola. I helped start it, along with 2 other consultants for RTI the US contractor, and 3 malariologists from the Angolan Ministry of Health. Since then PMI has expanded to cover 21 countries in Africa. The contract passed from RTI to Abt Associates, and others.
If you do simple math, that means we have accumulated about 1,000 person years since then, in Africa, fighting malaria. What a tremendous resource! Are you one of those people?
When Martinho Somandjinga, Manuel Lluberas, Joaquim Canelas and I started the US PMI in Angola in 2005, the excitement and pride of our accomplishments carried us along for the first couple of years. Sure we spent over two million dollars in one small province each year, but it seemed worth it.